# Jinfukang Oral Liquid Combined With Chemotherapy for Treating Driver Gene-negative Advanced NSCLC

> **NCT05098990** · PHASE4 · UNKNOWN · sponsor: **China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.** · enrollment: 328 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Jinfukang oral liquid
- **DRUG:** Platinum-based doublet chemotherapy

## Key facts

- **NCT ID:** NCT05098990
- **Lead sponsor:** China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-10-25
- **Primary completion:** 2024-06-15
- **Final completion:** 2024-08-15
- **Target enrollment:** 328 (ESTIMATED)
- **Last updated:** 2021-10-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05098990

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05098990, "Jinfukang Oral Liquid Combined With Chemotherapy for Treating Driver Gene-negative Advanced NSCLC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05098990. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*